Industry News

• Lilly to acquire European rights to Pfizer Animal Health assets  Elanco, the animal health division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products.
  Eli Lilly and Company March 08, 2010  
• Agilent Technologies' executive vice president and CFO Adrian Dillon to leave company  Agilent Technologies announced that Adrian T. Dillon will resign his position as executive vice president, finance and administration, and CFO, effective April 1. Dillon will become chief financial and administration officer at Skype, based in Luxembourg.
  Agilent Technologies Inc. March 05, 2010  
• Scientists find new form of prion disease that damages brain arteries   NIH scientists investigating how prion diseases destroy the brain have observed a new form of the disease in mice that does not cause the sponge-like brain deterioration typically seen in prion diseases. Instead, it resembles a form of human Alzheimer's disease.
  National Institutes of Health March 05, 2010  
• Johnson & Johnson Consumer Companies unveils CYTOMIMIC(TM) Technology  Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies have discovered how to harness the power of bioelectricity to help improve skin rejuvenation.
  Johnson & Johnson March 05, 2010  
• Chembio reports 2009 results  Total revenues were $13.83 million for the year ended December 31, 2009, which compares to total revenues of $11.05 million for the year ended December 31, 2008, a 25% increase.
  Chembio Diagnostics, Inc. March 05, 2010  
• ADVANCE-2 study results demonstrate investigational anticoagulant apixaban was superior  Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb and Pfizer, was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery.
  Pfizer Inc. March 04, 2010  
• Emergent BioSolutions reports financial results for full year 2009  For the full year 2009, total revenues were $234.8 million as compared to $178.6 million in 2008, and net income was $31.1 million, or $1.02 per share, as compared to $20.7 million, or $0.69 per share, in 2008.
  Emergent BioSolutions Inc. March 04, 2010  
• FDA approves name change for heartburn drug Kapidex  The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian.
  FDA March 04, 2010  
• District court upholds FDA's grant of 5-year market exclusivity to VYVANSE(R)  Shire announces that the United States District Court for the District of Columbia, following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration to grant 5-year New Chemical Entity exclusivity to lisdexamfetamine dimesylate.
  Shire plc March 04, 2010  
• BioReference Laboratories, Inc. reports sustained growth from all business units  The Company had net revenues for the quarter of $99,261, an increase of 31% over the $75,735 of net revenues recorded in the first quarter fiscal year 2009.
  BioReference Laboratories, Inc. March 04, 2010  

   (next 10 articles)